New chemo combo after pancreatic cancer surgery
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new chemotherapy combination (HR070803 plus two other drugs) given after surgery to see if it prevents pancreatic cancer from coming back better than the current standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove pancreatic cancer and all visible cancer was taken out (R0 or R1).
- You are physically active enough to be up and about at least half the day (ECOG 0 or 1).
- You can start treatment 3 to 12 weeks after your surgery.
- Your blood counts and organ function are within acceptable ranges.
- You have not received chemotherapy or radiation before surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
This clinical trial tests whether a combination of chemotherapy drugs (liposomal irinotecan, oxaliplatin, and S-1) is more effective than another standard chemotherapy combination (gemcitabine plus capecitabine) after surgery for pancreatic cancer. It aims to help prevent the cancer from coming back.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before and after surgery for people with pancreatic cancer that is at high risk of coming back but can still be surgically removed. The goal is to see if this treatment helps improve outcomes.
This trial tests whether combining radiation therapy with chemotherapy (called the GX regimen) after pancreatic cancer surgery helps prevent cancer from returning in patients with high-risk features. The study aims to see if this combination treatment improves outcomes compared to standard care.
This trial tests a new combination of drugs (NC410 plus chemotherapy and nivolumab, with or without ipilimumab) for people with metastatic pancreatic cancer who haven't had treatment yet. The goal is to see if adding these immunotherapy agents can help shrink or control the tumor.
This trial tests a new tumor vaccine (XH001) combined with standard chemotherapy after surgery for pancreatic cancer. The goal is to lower the chance of the cancer coming back.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.